Metrics to compare | AREC | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipARECPeersSector | |
|---|---|---|---|---|
P/E Ratio | −795.2x | −5.9x | −0.3x | |
PEG Ratio | −7.78 | −0.02 | 0.00 | |
Price/Book | 10.1x | 1.9x | 2.6x | |
Price / LTM Sales | 42.0x | 5.2x | 2.9x | |
Upside (Analyst Target) | 203.6% | 113.5% | 64.0% | |
Fair Value Upside | Unlock | 10.1% | 9.7% | Unlock |
Arecor Therapeutics plc, a clinical stage biotechnology company, develops therapeutics that address diabetes, obesity and other cardiometabolic diseases in the United Kingdom. The company’s lead therapeutic product is the AT278, a disruptor insulin which is designed to transform Automated Insulin Delivery (AID) systems to improve patient care for people living with diabetes. It also develops a novel oral delivery platform using a GLP-1 receptor agonist. Arecor Therapeutics plc was founded in 2007 and is headquartered in Little Chesterford, the United Kingdom.